Molecular assessment of Plasmodium falciparum resistance to antimalarial drugs in China.

Article Details

Citation
Copy to clipboard

Zhang GQ, Guan YY, Zheng B, Wu S, Tang LH

Molecular assessment of Plasmodium falciparum resistance to antimalarial drugs in China.

Trop Med Int Health. 2009 Oct;14(10):1266-71. doi: 10.1111/j.1365-3156.2009.02342.x.

PubMed ID
19772548 [ View in PubMed
]
Abstract

OBJECTIVE: In China, Chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) were abandoned for the treatment of falciparum malaria 20 years ago due to resistance. Subsequent field studies showed a trend of declining CQ and SP resistance in the country. The main purpose of this study was to analyse the molecular markers of antimalarial resistance and thereby to assess the possibility of reintroduction of CQ or SP for falciparum malaria treatment. METHODS: Plasmodium falciparum field isolates were collected in 2006-2007 from Hainan and Yunnan provinces, China. Nested PCR-sequencing assays were applied to analyse the SNPs in four genes: P. falciparum chloroquine resistance transporter (pfcrt) gene, multi-drug resistance 1 (pfmdr1) gene, dihydrofolate reductase (dhfr) gene and dihydropteroate synthetase (dhps) gene. RESULTS: We found the widespread presence of point mutations in the dhfr and dhps genes which are associated with SP treatment failure. The molecular analyses also showed the fairly high prevalence of point mutation in the pfcrt gene which is linked to CQ resistance. CONCLUSION: The results of the present study indicate that CQ and SP should not be reintroduced for falciparum malaria treatment in the near future in China.

DrugBank Data that Cites this Article

Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
SulfadoxineDihydropteroate synthetaseProteinPlasmodium falciparum
Yes
Not AvailableDetails